

# הכינוס התלת שנתי ה- X של

## החברה הישראלית לגינקולוגיה אונקולוגית

יום חמישי

30 ביוני 2016, כ"ד בסיון תשע"ו

מלון "דניאל", הרצליה



**חברי וועדה מארגנת:**

פרופ' טליה לוי - יו"ר

פרופ' עופר גמר

ד"ר אילן ברוכים

ד"ר מריו ביינר

ד"ר אורה רוזנגרטן

**וועדת שיפוט תקצירים ועבודות פרס בתחום הקליני,**

**מחקרי ופוסטר מצטיין:**

פרופ' עופר גמר – יו"ר

פרופ' טליה לוי

ד"ר אילן ברוכים

ד"ר מריו ביינר

ד"ר רמי איתן

ד"ר אמנון עמית

ד"ר אלון בן אריה

**ועדת בחירות:**

ד"ר רמי איתן, יו"ר

ד"ר אמנון עמית

ד"ר מיחאי מאירוביץ

## Invited speakers

## מרצים מוזמנים

### **Robert L. Coleman, M.D., FACOG, FACS**

Professor, Deputy Chair, Department of Gynecologic Oncology and Reproductive Medicine. Vice Chair, Clinical Research, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Prof. Coleman is a key opinion leader in cancers of the female genital tract. He has authored and co-authored over 400 scientific publications, including over 130 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks. Prof. Coleman serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national and international organizations including the Society of Gynecologic Oncology, the American College of Surgeons, American Association for Cancer Research, the American Society of Clinical Oncology, the International Gynecologic Cancer Society, European Society of Gynecologic Oncology and the European Society of Medical Oncology. In 2015, Prof. Coleman was the 47th President of the Society of Gynecologic Oncology (SGO) and fifth President of the Foundation for Gynecologic Oncology



### **Professor Dan Peer**

Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Director of the Focal Technology Area (FTA) on Nanomedicines for Personalized Theranostics, a National Nanotechnology Initiative and the Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund.

Prof. Peer's work was among the first to demonstrate systemic delivery of RNAi molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system.

Prof. Peer has more than 45 pending and granted patents. Some licensed to pharmaceutical companies and one is under a phase III clinical evaluation. In addition, based on his work, four spin-off companies were generated Leuko Biosciences, Quiet Therapeutics, SEPL Pharma and ART Bioscience aiming to bring nanomedicine into clinical practice.

Prof. Peer is currently the President of the *Israeli Chapter of the Controlled Release Society*, and a Member of the *Israel Young Academy of Sciences*.



# הכינוס התלת-שנתי ה - IX של החברה הישראלית לגינקולוגיה אונקולוגית

יום חמישי, 30 ביוני 2016, כ"ד בסיון תשע"ו, מלון "דניאל", הרצליה

## תוכנית הכינוס

08:00 – 08:50 התכנסות, רישום, כיבוד קל וסיור בתצרכה

08:50 – 09:00 דברי פתיחה  
פרופ' טליה לוי, יו"ר החברה הישראלית לגינקולוגיה אונקולוגית

09:00 – 10:00 **מושב!:** הצגת עבודות מקוריות  
יו"ר: ד"ר אמנון עמית, ד"ר מריו בינר, ד"ר רוני שפירא פרומר

### SENTINEL LYMPH NODE BIOPSY IN PATIENTS WITH ENDOMETRIAL CANCER: A FEASIBILITY STUDY

Shunit Armon<sup>1</sup>, Ami Munro<sup>2</sup>, Deborah Neesham<sup>2</sup>, Vivek Arora<sup>2</sup>,  
Ramaish Thangamani, Penny Blomfield<sup>3</sup>. Meir Lichtenstein, Nisha Jagasia,  
Gayanie Ratnayake<sup>2</sup>, Orla McNally<sup>2</sup>

<sup>1</sup>SZMC, Jerusalem, Israel; <sup>2</sup>RWH, Victoria Australia; <sup>3</sup>Royal Hobart Hospital, Tasmania,  
Australia

### EVALUATION OF MICROSCOPIC CHANGES IN FALLOPIAN TUBES OF PATIENTS WITH UTERINE PAPILLARY SEROUS CARCINOMA (USPC), BY COMPUTERIZED MORPHOMETRIC ANALYSIS

Amnon Amit<sup>1,3</sup>, Edmond Sabo<sup>2,3</sup>, Yamit Efrat Tamam<sup>1</sup>, Geula Klorin<sup>1,2</sup>.

<sup>1</sup>Department of Obstetrics & Gynecology; <sup>2</sup>Department of Pathology, Rambam Health Care  
Campus, Haifa, Israel; <sup>3</sup>Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel  
Institute of Technology, Haifa, Israel

### CANCER STEM CELLS IN ENDOMETRIAL CARCINOMA

Yael Naaman<sup>1</sup>, M. Huszar<sup>2</sup>, Ayelet Harari<sup>2</sup>, Or Y.<sup>1</sup>, Adva Cohen-Fredarow<sup>3</sup>,  
Nava Dekel<sup>3</sup>, Alon Ben-Arie<sup>1</sup>

<sup>1</sup>Department of Obstetrics & Gynecology, <sup>2</sup>Department of pathology, Kaplan Medical Center,  
Rehovot, Israel. <sup>3</sup>Department of Biological Regulation, Weizmann Institute of Science

### IL-6 AND MET BLOCKAGE REDUCE CHEMOTHERAPY-RESISTANCE AND ALTER CELL'S MOVEMENT IN OVARIAN AND UTERINE SEROUS CANCER

Yossi Levi<sup>1</sup>, Ilan Tsarfaty<sup>1</sup>, Ilan Bruchim<sup>2</sup>

<sup>1</sup>Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv  
University, Tel-Aviv, Israel, <sup>2</sup>Gynecologic Oncology Division and Laboratory of  
Gynecology Oncology, Department of Obstetrics and Gynecology, Hillel Yaffe Medical  
Center, Hadera, Affiliated to the Technion Israel Institute of Technology, Haifa, Israel

### QUALITATIVE ASSESSMENT VS. SUV MEASUREMENT OF FDG-UPTAKE IN SURGICALLY TREATED CERVICAL CANCER PATIENTS FOR PREDICTION OF PROGNOSTIC FACTORS

Oded Raban, Lina Salman, Gad Sabah, Roie Tzadok, Meital Nidam,  
Hana Bernstine, Ram Eitan

Gynecologic Oncology Division, Rabin Medical Center, Petah-Tikva, Tel-Aviv University, Tel-  
Aviv, Israel

## **CERVICAL CANCER EPIDEMIOLOGY IN FORMER SOVIET UNION IMMIGRANTS TO ISRAEL. A STEP TOWARDS SOLVING THE ENIGMA**

**Yael Raz**<sup>1</sup>, Lital Keinan-Boker<sup>2,3</sup>, Sophy Goren<sup>4</sup>, Daniel Cohen<sup>4</sup>, Dan Grisaru<sup>1</sup>

*<sup>1</sup>Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel-Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, <sup>2</sup>Israel Center for Disease Control, Ministry of Health, Gertner Institute, Sheba Medical Center, Ramat-Gan, Israel, <sup>3</sup>School of Public Health, Haifa University, Mt. Carmel, Haifa, Israel, <sup>4</sup>School of public health, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel*

## **ETHNIC DISPARITIES FOR GYNECOLOGIC CANCERS IN ISRAEL**

**Yfat Kadan**<sup>1</sup>, Barbara Silverman<sup>2</sup>, Limor Helpman<sup>1</sup>, Ami Fishman<sup>1</sup>.

*<sup>1</sup>Gynecologic Oncology unit, Meir Medical Center, Kefar Sava, <sup>2</sup>Israel national cancer registry, MOH, Israel*

הרצאת אורח 10:45 – 10:00

יו"ר: פרופ' עמי פישמן, ד"ר אורה רוזנגרטן, ד"ר שלומי שגיא

## **OPTIMIZING TREATMENT DECISIONS IN CERVICAL CANCER**

**Prof. Robert L. Coleman**, M.D., FACOG, FACS

*Vice Chair, Clinical Research and Deputy Chair, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

## **ASCO UPDATES ON GOG 213**

**Prof. Robert L. Coleman**, M.D., FACOG, FACS

11:10 – 10:45 כיבוד קף, סיוך בתצורה ופוסטריט

12:10 – 11:10 **מושב א! הצגת עבודות מקוריות**

יו"ר: ד"ר יעקב קורח, ד"ר אילן ברוכים, פרופ' תמר ספרא

## **LONG-TERM SURVIVORS OF ADVANCED HIGH-GRADE EPITHELIAL OVARIAN CANCER: CLINICAL CHARACTERISTICS**

**Yasmin Farhadian**, Tamar Perri, Gilad Ben-Baruch, Ronnie Shapira-Frommer, Mario E. Beiner, Benny Brandt, Ludmila Irmin, Nissim Zmira, Jacob Korach

*Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

## **PROGNOSTIC FACTORS FOR PREDICTING OPTIMAL CYTOREDUCTION IN OVARIAN CANCER PATIENTS**

**Effi Yeoshoua**, Oded Raban, Ariella Jakobson-Setton, Gad Sabah,

Dalia Tsoref, Guy Cohen, Ram Eitan

*Gynecologic Oncology Division, Rabin Medical Center, Petah Tikva, Tel- Aviv University, Tel-Aviv, Israel*

## **OUTCOME OF OVARIAN AND PRIMARY PERITONEAL CARCINOMA PATIENTS WHO DID NOT RESPOND TO NEOADJUVANT CHEMOTHERAPY PRIOR TO INTERVAL DEBULKING SURGERY**

**Michal Levy**<sup>1</sup>, Joseph Menczer<sup>1</sup>, Ayelet Vandel<sup>2</sup>, Yossi Mizrahi<sup>1</sup>,

Erez Ben-Shem<sup>1</sup>, Ofri Peled<sup>1</sup>, Tally Levy<sup>1</sup>

*<sup>1</sup>Division of Gynecologic Oncology and <sup>2</sup>Department of Roentgenology, E. Wolfson Medical Center, Holon, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

## **SILENT POLYMORPHISM IN THE BCL2 GENE DETERMINES RESPONSE TO CHEMOTHERAPY IN HIGH GRADE SEROUS CARCINOMA**

Rotem Ben-Hamo<sup>1</sup>, Alona Zilberberg<sup>1</sup>, Helit Cohen<sup>1</sup>, Keren Bahar-Shany<sup>2</sup>, Jacob Korach<sup>3</sup>, Sarit Aviel-Ronen<sup>4</sup>, Iris Barshack<sup>4,5</sup>, Alon Zilka<sup>7</sup>, **Keren Levanon**<sup>2,5\*</sup>, Sol Efroni<sup>1\*</sup>

<sup>1</sup>The Mina and Everard Goodman Faculty of Life Science, Bar Ilan University, Ramat-Gan, <sup>2</sup>Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat-Gan, <sup>3</sup>Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat-Gan, <sup>4</sup>Department of Pathology, Chaim Sheba Medical Center, Ramat-Gan <sup>5</sup>Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. <sup>7</sup>The flow cytometry, affinity measurement and Cell imaging unit, NIBN, Ben-Gurion University of the Negev, Beer-Sheva, Israel. \* Equal contribution

## **THE COMBINED EFFECT OF DENDRITIC CELLS AND IGF1 RECEPTOR INHIBITOR ON OVARIAN CANCER PROLIFERATION**

**Muna Alemi Yahya**<sup>1,2</sup>, Shilhav Meisel Sharon<sup>2</sup>, Shay Hantisteanu<sup>2</sup>, Mordechai, Hallak<sup>1,2</sup>, Haim Werner<sup>3</sup>, Ilan Bruchim<sup>1,2,3</sup>

<sup>1</sup>Gynecologic Oncology Division and <sup>2</sup>Laboratory of Gynecology Research, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Affiliated to the Technion Israel Institute of Technology, Haifa, Israel, <sup>3</sup>Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

## **COMPLEMENTARY TREATMENT FOR STRESS REDUCTION IN WOMEN WITH OVARIAN CANCER– ASSESSMENT WITH HEART RATE VARIABILITY**

**Amnon Amit**<sup>1,2</sup>, Lior Lowenstein<sup>1,2</sup>, Keren Or Chen<sup>3</sup>, Geula Korin<sup>1</sup>, Amir Weissman<sup>1,2</sup>

<sup>1</sup>Department of Obstetrics & Gynecology, Rambam Health Care Campus, Haifa, Israel; <sup>2</sup>Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel; <sup>3</sup>Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel

## **SAFETY OF HERBAL MEDICINE USE DURING CHEMOTHERAPY IN PATIENTS WITH GYNECOLOGICAL CANCER: A "BEDSIDE-TO-BENCH" APPROACH**

Eran Ben-Arye<sup>1,2</sup>, Ofer Lavie<sup>3</sup>, Noah Samuels<sup>1,4</sup>, **Yakir Segev**<sup>3</sup>, Hazem Khamaisie<sup>5</sup>, Elad Schiff<sup>6</sup>, Orit Gressel Raz<sup>1</sup>, Jamal Mahajna<sup>5,7</sup>

<sup>1</sup>Integrative Oncology Program, Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; <sup>2</sup> Complementary and Traditional Medicine Unit, Department of Family Medicine, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; <sup>3</sup>Gynecological oncology unit, Department of Obstetrics and Gynecology, Gynecologic Oncology Service, Carmel Medical Center, Haifa, Israel; <sup>4</sup>Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; <sup>5</sup>Cancer Drug Discovery Program, Galilee Technology Center (Migal), Kiryat Shmona, Israel; <sup>6</sup>Departments of Internal Medicine and Integrative Surgery Service, Bnai Zion Hospital, Haifa, Israel; <sup>7</sup>Nutritional Sciences department, Tel Hai College, Kiryat Shmona, Israel

הרצאת אורח 12:40 – 12:10

יו"ר: פרופ' טליה לוי, פרופ' דוד שניידר, ד"ר אבי בן שושן

## **NANOMEDICINE AS AN EMERGING PLATFORM FOR ANTI-CANCER THERAPY**

**Prof. Dan Peer**

Faculty of Life Science, Department of Cell Research & Immunology, Tel-Aviv University, Tel-Aviv, Israel



12:40 – 13:20 **מושב III: הצגת עבודות מקוריות**  
יו"ר: פרופ' עופר גמר, פרופ' עופר לביא, ד"ר טל ציון

**THE HETEROGENEITY OF CANCER STEM CELL MARKERS IN EPITHELIAL OVARIAN CANCER**

**Osnat Elyashiv**<sup>1</sup>, Milo D. Landesman<sup>2</sup>, M. Smriti Singh<sup>2</sup>, D. Peer<sup>2</sup>, T. Levy<sup>1</sup>  
<sup>1</sup>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, <sup>2</sup>Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel-Aviv University

**DOES MUCINOUS HISTOLOGY WORSEN PROGNOSIS IN BORDERLINE OVARIAN TUMORS?**

**L. Helpman**<sup>1,2,3</sup>, M.E. Beiner<sup>1,2</sup>, A. Yaniv<sup>2</sup>, T. Perri<sup>1,2</sup>, S. Aviel-Ronen<sup>1,2</sup>, L. Irmin<sup>1</sup>, N. Zmira<sup>1</sup>, J. Korach<sup>1,2</sup>, G. Ben-Baruch<sup>1,2</sup>.  
<sup>1</sup>Chaim Sheba Medical Center, Tel-Hashomer, Israel; <sup>2</sup>Tel-Aviv University, Tel-Aviv, Israel; <sup>3</sup>Meir Medical Center, Kfar Saba, Israel

**SENTINEL LYMPH NODE BIOPSY IN VULVAR CANCER: A MULTICENTER EVALUATION OF PROCEDURE'S FEASIBILITY FOR ISRAELI PATIENTS**

**Yael Raz**<sup>1</sup>, Guy Bibi<sup>1</sup>, Alon Ben-Arie<sup>2</sup>, Michai Meirovitz<sup>3</sup>, Schlomo Schneebaum<sup>4</sup>, Dan Grisaru<sup>1</sup>  
<sup>1</sup> Department of Obstetrics and Gynecology, Lis maternity hospital, Tel-Aviv Sourasky Medical Center, affiliated to the Sackler faculty of medicine, Tel-Aviv University, Tel-Aviv, Israel.<sup>2</sup> Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Israel, affiliated to the Hebrew university "Hadassah" medical school, Jerusalem, Israel.<sup>3</sup> Department of Obstetrics and Gynecology, Soroka Medical Center, affiliated to Ben Gurion University of the Negev, Beer-Sheva, Israel.<sup>4</sup> Radio guided Surgery unit, Department of Surgery, Tel-Aviv Sourasky Medical Center, affiliated to the Sackler faculty of medicine, Tel-Aviv University, Tel-Aviv, Israel

**CANCER CELL REVERSION BY PLACENTA-DERIVED MICRO-ENVIRONMENTAL MOLECULES**

S. Cohen, **Yakir Segev**, A. Damti, M. Paz, I. Feferkorn, G. Kligun, M. Schmidt, N. Boms-Yonai, A. Kaldawy, R. Kedar, R. Auslender, O. Lavie  
Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel

**IS THERE AN ASSOCIATION BETWEEN RECURRENT PREGNANCY LOSS AND FUTURE RISK FOR FEMALE MALIGNANCIES?**

**Charach R.**<sup>1</sup>, Kessous R.<sup>1</sup>, Beharier O.<sup>1</sup>, Sergienko R.<sup>2</sup>, Sheiner E.<sup>1</sup>  
<sup>1</sup>Department of Obstetrics and Gynecology, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel; <sup>2</sup>Ben-Gurion University of the Negev, Department of public health, Beer-Sheva, Israel; <sup>3</sup>Soroka University Medical Center, Clalit Health Services (Southern District), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

**LAPAROSCOPIC MANAGEMENT OF INVASIVE MOLE PERFORATING THE UTERUS**

**Leonti Grin**, Ahmed Namazov, Michael Voldarsky, Eyal Anteby, Ofer Lavie, Ofer Gemer  
Department of Obstetrics and Gynecology, Barzilai Medical Center, Ben-Gurion University, Ashkelon, Israel

13:30 – 13:20 **סיכום פעילות הוועד היוצא**  
**פרופ' טליה לוי, יו"ר החברה הישראלית לגינקולוגיה אונקולוגית**

14:15 – 13:30 **ארוחת 3הריט**

14:45 – 14:15 הרצאת אורח

יו"ר: פרופ' עוזי בלר, פרופ' דני גריסרו, ד"ר צבי וקנין

**IMPACT OF THE ADOPTION OF AN INDIVIDUALIZED PRIMARY SURGICAL TRIAGE ALGORITHM IN ADVANCED OVARIAN CANCER: THE MDACC EXPERIENCE**

**Prof. Robert L. Coleman, M.D., FACOG, FACS**

*Vice Chair, Clinical Research and Deputy Chair, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

Tumor board 15:25 – 14:45

מנחה: ד"ר מיחאי מאירוביץ

מדיינים: פרופ' רוברט קולמן, ד"ר אלון בן אריה, ד"ר רמי איתן, ד"ר ענבר בן שחר.

הצגות מקרים: ד"ר אילן אטלס, ד"ר יהודה בן דוד, ד"ר לימור הלפמן

15:30 – 15:25 חלוקת פרסים לעבודות המצטיינות  
פרופ' עופר גמר, יו"ר וועדת תקצירים

תוצאות בחירות  
ד"ר רמי איתן, יו"ר וועדת בחירות

סיום